会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Radiohalogenated for proteins
    • 放射性卤化蛋白质
    • US4885153A
    • 1989-12-05
    • US338497
    • 1989-04-13
    • Daniel S. WilburAlan R. FritzbergDavid S. Jones
    • Daniel S. WilburAlan R. FritzbergDavid S. Jones
    • C07F3/12C07F7/22
    • C07F7/2212C07F3/12
    • Haloaryl compounds bearing a defined functional group or precursor are metalated with either Sn(n-Bu).sub.3 or SnMe.sub.3. The resulting aryltin compound may be transmetalated in site-specific reaction with one of the following organometallic groups: HgX.sub.2, Hg(OAc).sub.2, BX.sub.3, or BZ.sub.3, wherein X is Cl, Br, or I, and Z is alkyl or alkoxy. The stannylated or otherwise metalated compounds are subsequently radiohalogenated via a demetalation reaction. The Stannylated or otherwise metalated compounds are subsequently radiohalogenated via a demetalation reaction. The functional group is suitable for conjugation to protein and can be present or be added subsequent, but most preferably prior, to the radiohalogenation.Also compounds of the formula: R.sub.1 --Ar--R.sub.2, wherein R.sub.1 is either a radiohalogen or any one of the organometallic groups stated above, Ar is aromatic or heteroaromatic ring, and R.sub.2 is a short-chain substituent that does not highly activate the aromatic ring an that bears a functional group suitable for conjugation to protein under conditions that preserve the biological activity of the protein. The radiohalogenated small nolecules are conjugated to proteins such as monoclonal antibodies for use in diagnosis and therapy.
    • 带有限定官能团或前体的卤代芳基化合物与Sn(n-Bu)3或SnMe 3金属化。 所得的芳基锡化合物可以与以下有机金属基团之一的位置特异性反应转金属:HgX2,Hg(OAc)2,BX3或BZ3,其中X为Cl,Br或I,Z为烷基或烷氧基。 然后通过脱金属反应使经卤化或其它金属化的化合物放射性卤化。 然后通过脱金属反应使经卤化或其它金属化的化合物放射性卤化。 该官能团适用于与蛋白质缀合,并且可以存在或随后添加,但最优选之前为放射性卤化。 还有下式的化合物:R1-Ar-R2,其中R1是放射性卤素或上述有机金属基团中的任一个,Ar是芳族或杂芳族环,R2是不高度活化芳族的短链取代基 在保护蛋白质的生物活性的条件下,具有适合于与蛋白质缀合的官能团。 放射性卤化的小分子与蛋白质缀合,例如用于诊断和治疗的单克隆抗体。
    • 5. 发明授权
    • Radiohalogenated small molecules for protein labeling
    • 用于蛋白标记的放射性卤代小分子
    • US5045303A
    • 1991-09-03
    • US137952
    • 1987-11-23
    • Daniel S. WilburAlan R. Fritzberg
    • Daniel S. WilburAlan R. Fritzberg
    • C07F3/12C07F7/22
    • C07F7/2212C07F3/12
    • Haloaryl compounds are lithiated and thereafter metalated with one of the following organometallic groups: Sn(n-Bu).sub.3 or SnMe.sub.3. The resulting aryltin compound can be transmetalated in site-specific reaction with one of the following organometallic groups: HgX, Hg(OAc).sub.2, BX.sub.3, or BZ.sub.2, wherein X is Cl, Br, or I, and Z is alkyl or alkoxy. The metalated compounds are subsequently radiohalogenated via a demetalation reaction. A functional group suitable for conjugation to protein can be added subsequent of preferably prior to the radiohalogenation.Also compounds of the formula: R.sub.1 -Ar-R.sub.2, wherein R.sub.1 is either a radiohalogen or any one of the organometallic groups stated above, Ar is aromatic or heteroaromatic ring, and R.sub.2 is a short-chain substituent that does not activate the aromatic ring and that bears a functional group, or a precursor thereof, suitable for conjugation to protein under conditions that preserve the biological activity of the protein.The radiohalogenated small molecules are conjugated to proteins such as monoclonal antibodies for use in diagnosis and therapy.
    • 卤代芳基化合物被锂化,然后用以下有机金属组之一金属化:Sn(n-Bu)3或SnMe 3。 所得的芳基锡化合物可以在以下有机金属基团之一的位置特异性反应中转金属:HgX,Hg(OAc)2,BX3或BZ2,其中X为Cl,Br或I,Z为烷基或烷氧基。 金属化合物随后通过脱金属反应放射卤化。 适合于与蛋白质缀合的官能团可以随后优选在放射性卤化之前加入。 还有下式的化合物:R1-Ar-R2,其中R1是放射性卤素或上述有机金属基团中的任何一个,Ar是芳族或杂芳族环,R2是不活化芳环的短链取代基 并且在保持蛋白质的生物活性的条件下具有适合于与蛋白质缀合的官能团或其前体。 放射性卤化的小分子与蛋白质缀合,例如用于诊断和治疗的单克隆抗体。
    • 6. 发明授权
    • Radiohalogenated small molecules for protein labeling
    • 放射性蛋白标记的小分子
    • US5213787A
    • 1993-05-25
    • US627806
    • 1990-12-12
    • Daniel S. WilburAlan R. Fritzberg
    • Daniel S. WilburAlan R. Fritzberg
    • C07F3/12C07F7/22
    • C07F7/2212C07F3/12
    • Haloaryl compounds are lithiated and thereafter metalated with one of the following organometallic groups: Sn(n-Bu).sub.3 or SnMe.sub.3. The resulting aryltin compound can be transmetalated in site-specific reaction with one of the following organometallic groups: HgX, Hg(OAc).sub.2, BX.sub.3, or BZ.sub.2, wherein X is Cl, Br, or I, and Z is alkyl or alkoxy. The metalated compounds are subsequently radiohalogenated via a demetalation reaction. A functional group suitable for conjugation to protein can be added subsequent or preferably prior to the radiohalogenation.Also compounds of the formula: R.sub.1 -Ar-R.sub.2, wherein R.sub.1 is either a radiohalogen or any one of the organometallic groups stated above, Ar is aromatic or heteroaromatic ring, and R.sub.2 is a short-chain substituent that does not activate the aromatic ring and that bears a functional group, or a precursor thereof, suitable for conjugation to protein under conditions that preserve the biological activity of the protein.The radiohalogenated small molecules are conjugated to proteins such as monoclonal antibodies for use in diagnosis and therapy.
    • 卤代芳基化合物被锂化,然后用以下有机金属组之一金属化:Sn(n-Bu)3或SnMe 3。 所得的芳基锡化合物可以在以下有机金属基团之一的位置特异性反应中转金属:HgX,Hg(OAc)2,BX3或BZ2,其中X为Cl,Br或I,Z为烷基或烷氧基。 金属化合物随后通过脱金属反应放射卤化。 适于与蛋白质缀合的官能团可以随后或优选在放射性卤化之前添加。 还有下式的化合物:R1-Ar-R2,其中R1是放射性卤素或上述有机金属基团中的任何一个,Ar是芳族或杂芳族环,R2是不活化芳环的短链取代基 并且在保持蛋白质的生物活性的条件下具有适合于与蛋白质缀合的官能团或其前体。 放射性卤化的小分子与蛋白质缀合,例如用于诊断和治疗的单克隆抗体。